Sites Around the World
Sites Around the World
Search
Veterinary Public Health
Veterinary Public Health
Outside the lab…inside the family
We are a manufacturing and a research company too. Outside of the lab, we have engineers, legal teams, logistics managers, QA/QC teams and more.
COVID-19: Ivermectin in Animal Health products
Boehringer Ingelheim manufactures several veterinary products containing ivermectin. They are not approved or suitable for use in humans to try to prevent or treat COVID-19.
Annual Results Press Conference
Boehringer Ingelheim presents the results of business development and gives an outlook for the coming year.
Experts in microbial technology | Bioxcellence | Boehringer Ingelheim
Meet one BioXcellence expert in microbial development and manufacturing. Explore our broad commercial experience and development competence.
Partnering with Boehringer Ingelheim: BIO International 2024
Learn about innovation and partnering with Boehringer Ingelheim human pharma, animal health and biopharma contract manufacturing at BIO International 2024
History
History
About Our Business| Bioxcellence | Boehringer Ingelheim
BioXcellence, reliable contract development & manufacturing partner to the pharmaceutical industry. A trusted partner through the Lifecyle of your product.
Shanghai
Shanghai serves as an important hub for all of the company’s three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing.
Global Network | Bioxcellence | Boehringer Ingelheim
Our network of manufacturing facilities spans the globe, from Fremont, in the United States to Biberach in Germany, Vienna in Austria and Shanghai in China
Media & News | Bioxcellence | Boehringer Ingelheim
Stay updated with BioXcellence Media & News. Explore the latest industry trends & news in global biopharmaceutical contract manufacturing. Don't miss out!
Boehringer biopharmaceuticals China receives approval supply EU and US
Boehringer Ingelheim Biopharmaceuticals China receives approval for supply of EU and US markets
Microbial expertise
Microbial systems are ideal for synthesizing smaller and non-glycosylated proteins, complementing mammalian cell processes for larger proteins like monoclonal antibodies.
Fremont
Upstream process development in a high throughput automated bioreactor system.
inauguration_biopharmaceutical_production_facility_vienna
The state-of-the-art biopharmaceutical production facility in Vienna is the single largest investment in the company's history.
Development Biotechnology sustainable cell culture
Boehringer Ingelheim refines its bioprocess technology operations in Animal Health with greater focus on environmental sustainability to reduce footprint
Duluth
Duluth
Classical Swine Fever live vaccine approved in China
Boehringer Ingelheim’s China-developed Classical Swine Fever live vaccine approved
Monoclonal Antibody Production | Bioxcellence | Boehringer Ingelheim
Explore our advanced capabilities in antibody production, and learn about the unique features of monoclonal & polyclonal antibodies.
Who are we?
Started in 1885 by Albert Boehringer, this independent family-owned company has grown into a top contributor in Human Pharma and Animal Health.
Boehringer Olaf Scholz break ground for innovation center
Boehringer Ingelheim and German Chancellor Olaf Scholz lay the foundation stone for 285 million EUR innovation center
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Large Scale Cell Culture Facility | Bioxcellence | Boehringer Ingelheim
Tour our Large Scale Cell Culture Facility in Vienna, Austria, advancing biopharmaceutical production with cutting-edge cell culture technology.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.